GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tanvex BioPharma Inc (TPE:6541) » Definitions » EV-to-Revenue

Tanvex BioPharma (TPE:6541) EV-to-Revenue : 243.21 (As of Jun. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Tanvex BioPharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Tanvex BioPharma's enterprise value is NT$8,422.44 Mil. Tanvex BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was NT$34.63 Mil. Therefore, Tanvex BioPharma's EV-to-Revenue for today is 243.21.

The historical rank and industry rank for Tanvex BioPharma's EV-to-Revenue or its related term are showing as below:

TPE:6541' s EV-to-Revenue Range Over the Past 10 Years
Min: 129.04   Med: 1565.75   Max: 93984.11
Current: 243.21

During the past 11 years, the highest EV-to-Revenue of Tanvex BioPharma was 93984.11. The lowest was 129.04. And the median was 1565.75.

TPE:6541's EV-to-Revenue is ranked worse than
89.68% of 1037 companies
in the Biotechnology industry
Industry Median: 7.83 vs TPE:6541: 243.21

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-06), Tanvex BioPharma's stock price is NT$40.70. Tanvex BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was NT$0.26. Therefore, Tanvex BioPharma's PS Ratio for today is 156.54.


Tanvex BioPharma EV-to-Revenue Historical Data

The historical data trend for Tanvex BioPharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tanvex BioPharma EV-to-Revenue Chart

Tanvex BioPharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 37,016.56 3,702.13 599.51 164.01

Tanvex BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 219.59 167.57 161.56 164.01 238.53

Competitive Comparison of Tanvex BioPharma's EV-to-Revenue

For the Biotechnology subindustry, Tanvex BioPharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tanvex BioPharma's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's EV-to-Revenue falls into.



Tanvex BioPharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Tanvex BioPharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8422.443/34.63
=243.21

Tanvex BioPharma's current Enterprise Value is NT$8,422.44 Mil.
Tanvex BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$34.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tanvex BioPharma  (TPE:6541) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Tanvex BioPharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=40.70/0.26
=156.54

Tanvex BioPharma's share price for today is NT$40.70.
Tanvex BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.26.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tanvex BioPharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tanvex BioPharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Tanvex BioPharma (TPE:6541) Business Description

Traded in Other Exchanges
N/A
Address
No. 376, Ren'ai Road, Section 4, 13th Floor-1, Da'an District, Taipei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others.

Tanvex BioPharma (TPE:6541) Headlines

No Headlines